Immunic Meets Nasdaq's Minimum Bid Price Requirement, Regains Compliance

Immunic, Inc. announced that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after the closing bid price of its common stock was at $1.00 per share or greater for at least 20 consecutive business days. The company is developing novel oral therapies for neurologic diseases, including vidofludimus calcium for relapsing multiple sclerosis. Top-line data for this program is expected by the end of 2026.